SAVE MONEY ON TRAVEL DEALS

Attorneys for Johnson & Johnson said Abbott's rheumatoid arthritis drug Humira, one of the top-selling drugs in the world, was made using technology developed exclusively for Johnson & Johnson at New York University.

Humira earned more than $4 billion in sales in 2008. It differs from Johnson & Johnson's product Remicade, as it is fully derived from human DNA, the Chicago Tribune reported Tuesday.

Remicade, which earned $5 billion last year, is made partially using the DNA of mice, Abbott's lawyers said.

Johnson & Johnson was not seeking to have Abbott stop making the medicine, which is also used for autoimmune disorders, like Crohn's disease.

The company was seeking a monetary settlement, which still allows Abbott to earn profits, Johnson & Johnson's attorneys said.

Abbott already paid nearly $7 billion to purchase Humira, which it got by acquiring Knoll Pharmaceuticals in 2001.

 BREAKING STORIES

Monarchs returning in record low numbers

Police: Ex-worker disabled cars via Web

Police: Ex-worker disabled cars via Web

Police send drugs to resale shop

Study: Some pipefish dads can be deadbeats

Blockbuster says bankruptcy is possible

2010 energy prize competition begins

Hormone hikes cotton yields in droughts

Apparent cause determined for Texas quakes

New types of bandages and wraps developed

Cadets honor 155-mile march in Texas

Conservation measures due for Bush center

Seismologists tie well to DFW earthquakes

Whole genome sequencing diagnosis achieved

Veteran accused of violating probation

NASA extends Johnson safety contract

Two people hurt during bull's escape

Twitter key tie to world, astronauts say

Obama touts green jobs as key to recovery

Cystoscopy suffices for bladder cancer